Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose–response study and open-label extension study

被引：0
|
作者：
Takashi Wada
Masaya Inagaki
Toru Yoshinari
Ryuji Terata
Naoko Totsuka
Miki Gotou
Gaia Hashimoto
机构：
[1] Kanazawa University,Department of Nephrology and Laboratory Medicine
[2] Mitsubishi Tanabe Pharma Corporation,Data Science Department, Ikuyaku. Integrated Value Development Division
[3] Mitsubishi Tanabe Pharma Corporation,Clinical Research and Development II Department, Ikuyaku. Integrated Value Development Division
来源：
Clinical and Experimental Nephrology | 2021年 / 25卷
关键词：
Diabetic nephropathy; Diabetic kidney disease; Dose-finding study; Fibrosis; Mineralocorticoid receptor antagonists; Apararenone;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：120 / 130
页数：10
相关论文
共 50 条
  • [41] A Double-Blind, Randomized, Placebo-Controlled Clinical Trial on Benfotiamine Treatment in Patients With Diabetic Nephropathy
    Alkhalaf, Alaa
    Klooster, Astrid
    van Oeveren, Willem
    Achenbach, Ulrike
    Kleefstra, Nanne
    Slingerland, Robbert J.
    Mijnhout, G. Sophie
    Bilo, Henk J. G.
    Gans, Reinold O. B.
    Navis, Gerjan J.
    Bakker, Stephan J. L.
    DIABETES CARE, 2010, 33 (07) : 1598 - 1601
  • [42] A randomized, double-blind, placebo-controlled, dose-response study with formoterol turbuhaler(R).
    Kemp, JP
    Chervinsky, P
    Nelson, H
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1997, 99 (01) : 1343 - 1343
  • [43] Baricitinib in Patients with Systemic Lupus Erythematosus: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
    Wallace, Daniel J.
    Furie, Richard
    Tanaka, Yoshiya
    Kalunian, Kenneth C.
    Mosca, Marta
    Petri, Michelle
    Dorner, Thomas
    Cardiel, Mario H.
    Bruce, Ian N.
    Gomez, Elisa
    DeLozier, Amy M.
    Janes, Jonathan
    Linnik, Matthew D.
    de Bono, Stephanie
    Silk, Maria E.
    Hoffman, Robert W.
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [44] The effect of ubiquinone in diabetic polyneuropathy: A randomized double-blind placebo-controlled study
    Hernandez-Ojeda, Jaime
    Cardona-Munoz, Ernesto G.
    Roman-Pintos, Luis M.
    Troyo-Sanroman, Rogelio
    Ortiz-Lazareno, Pablo C.
    Cardenas-Meza, Mario A.
    Pascoe-Gonzalez, Sara
    Miranda-Diaz, Alejandra G.
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2012, 26 (04) : 352 - 358
  • [45] ELAMIPRETIDE IN PATIENTS WITH BARTH SYNDROME: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL FOLLOWED BY 36-WEEK OPEN-LABEL EXTENSION
    Thompson, Reid
    Manuel, Ryan
    Aiudi, Anthony
    Jones, John J.
    Carr, Jim
    Hornby, Brittany
    Vernon, Hilary
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 957 - 957
  • [46] Effect of Denosumab on Structure Modification in Erosive Hand Osteoarthritis: Results of a 48-Week, Monocentric, Randomized, Placebo-controlled, Double-blind Phase 2 Study and Open Label Extension Phase
    Wittoek, Ruth
    Verbruggen, August
    Vanhaverbeke, Tine
    Elewaut, Dirk
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4540 - 4542
  • [47] EFFECT OF DENOSUMAB ON STRUCTURE MODIFICATION IN EROSIVE HAND OSTEOARTHRITIS: RESULTS OF A 48-WEEKS, MONOCENTRIC, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND PHASE 2 STUDY AND OPEN LABEL EXTENSION PHASE
    Wittoek, R.
    Verbruggen, G.
    Vanhaverbeke, T.
    Elewaut, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 48 - 49
  • [48] Elamipretide (ELAM) in Subjects With Barth Syndrome (TAZPOWER): A Phase 2 Randomized, Double-Blind, Placebo-Controlled Crossover Trial Followed by an Open-Label Treatment Extension
    Vernon, Hilary J.
    Thompson, William Reid
    Hornby, Brittany
    CIRCULATION, 2018, 138
  • [49] A Randomized, Double-Blind, Placebo-Controlled Study of Cilostazol in the Treatment of Nephropathy in Chinese Patients with Type 2 Diabetes
    Luk, Andrea O. Y.
    So, Wing-Yee
    Ozaki, Risa
    Yeung, Chun-Yip
    Choi, Kai
    Kong, Alice P. S.
    Ma, Ronald C. W.
    Chan, Juliana C. N.
    Tong, Peter C. Y.
    DIABETES, 2010, 59 : A252 - A252
  • [50] Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy
    Zhang, Hong
    Rizk, Dana, V
    Perkovic, Vlado
    Maes, Bart
    Kashihara, Naoki
    Rovin, Brad
    Trimarchi, Hernan
    Sprangers, Ben
    Meier, Matthias
    Kollins, Dmitrij
    Papachristofi, Olympia
    Milojevic, Julie
    Junge, Guido
    Nidamarthy, Prasanna Kumar
    Charney, Alan
    Barratt, Jonathan
    KIDNEY INTERNATIONAL, 2024, 105 (01) : 189 - 199
12345